You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testing

    SBC: HEMEX HEALTH INC            Topic: NIDDK

    PROJECT SUMMARY Diabetes is one of the most important health issues in the worldIt is a disease that disproportionately affects low and middle income countriesNot only is diabetes a major cause of morbidity and mortalityit can devastate the finances of families and strain countriesfinancial resourcesKey components for addressing this healthcare crises include early diagnosis as well as ongoing mon ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Poloxamer 188 mechanism of action in ischemic heart failure.

    SBC: PHRIXUS PHARMACEUTICALS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): This project was initiated to determine how Poloxamer-188 (P-188) improves cardiac function in ischemic heart failure (HF). While it is accepted that lack of oxygen (ischemia) results in tissue damage, the direct involvement of membrane injury in the progression of ischemic HF is a relatively novel concept. The long-term goal of this project is to establish a r ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Point of care detection of extracellular vesicles in urine for diagnosis of preeclampsia

    SBC: Sersense Inc            Topic: NICHD

    PreeclampsiaPEis a pregnancy specific disorder characterized by hypertension and commonly by the appearance of urinary proteinThis disorder occurs inof pregnancies worldwide and is the second leading cause of maternal fetal morbidity and mortality worldwideIn low resource settingsPE accounts for up toof maternal deathsThe etiology of this disease is poorly understoodThis confounds therapeutic inte ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Point-of-Care Carotid Ultrasound and Cardiovascular Risk Assessment Device

    SBC: ARBOR ULTRASOUND TECHNOLOGIES, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): This proposal describes a novel, low-cost, high-performance compact carotid ultrasound imaging system to meet the clinical point-of-care needs for stenosis assessment based upon consensus practice criteria guidelines. At the same time, this system will meet the growing need for advanced cardiovascular (CV) risk assessment. This research integrates proven fundam ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Plant-Derived Estrogens and Cell Proliferation

    SBC: BIONOVO, INC.            Topic: NCCAM

    DESCRIPTION (provided by applicant): Menopause is associated with about a 10-15 pound weight gain and a redistribution of fat to the abdomen. The increase in abdominal fat, also known as visceral fat is known to produce cytokines that cause inflammation which can lead to the metabolic syndrome. The metabolic syndrome represents a major public health burden because it increases the risk of cardiova ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Piezoelectric Pump to supply Ventricular Assist Device for Fontan Patients

    SBC: KINETIC CERAMICS, LLC            Topic: NINR

    DESCRIPTION (provided by applicant): Congenital cardiovascular defects, specifically single ventricle abnormalities, constitute the most common cause of death among infants born with birth defects. Even after surgically rerouting the single ventricle circulation via the Fontan procedure, the circulation in these patients relies on blood flowing passively through the lungs. Thus, this group of pati ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Peripheral FAAH inhibitor, URB937, as an opioid-sparing analgesic for chronic pain.

    SBC: ASPIREBIO CORP            Topic: 101

    PROJECT SUMMARY Opioid drugs are powerful analgesicsbut their side effect profile strongly limits their useIndeedtheir addictive properties have led to an epidemic of abuse in the US that accounts forof the global utilization of prescription opioid analgesics in the USwith a market of over $billion per yearPrevious studies have shown that the endocannabinoid neurotransmitteranandamidecontrols noci ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTION (provided by applicant): Pain management remains a significant unmet medical need. Anandamide is an endogenous marijuana-like ('endocannabinoid') molecule that plays important roles in the regulation of pain. Previous work has shown that endocannabinoid receptors located outside the central nervous system (CNS) exert a powerful regulatory control over pain initiation. Moreove ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Oxygen Production and Delivery on Demand

    SBC: GLOBAL RESEARCH & DEVELOPMENT INC            Topic: DHA17B005

    This proposal is in response to the Defense Health Agency 2017 Phase I SBIR topic 17B-005.The approach is the use of a membrane oxygen pump using newly developed nano-thickness membranes with all the layers less than 1 micron total.Nanometer thickness membranes enable more oxygen output per surface area at temperatures of 300-600 C than current state-of-the -art 600-800 C membranes that are 50-300 ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  10. Optimization of Protein Therapeutic Formulations

    SBC: SOLUBLE THERAPEUTICS, INC            Topic: NIGMS

    DESCRIPTION (provided by applicant): This proposal involves the development and validation of a novel approach to improve and accelerate the discovery of biopharmaceuticals (i.e. vaccines, monoclonal antibodies and other therapeutic proteins). Biopharmaceuticals are used to treat a variety of infectious and chronic diseases. The proposed research is intended to establish a new paradigm for rapidly ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government